Evidence map›Paper›PMID 40475131›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Understanding the pathogenesis of uveitis in Ebola virus disease survivors: a study protocol for clinical, molecular virologic, and immunologic characterization.

Caleb D Hartley, Susanne Linderman, Tolulope Fashina, Laura Ward, Carolyn Drews-Botsch, Catherine Pratt, Sanjana Kuthyar, Alcides Filho Fernandes, Ye Huang, Charlene Choo and 31 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

41 authors.

Caleb D HartleyDepartment of Ophthalmology and Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Susanne LindermanDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Tolulope FashinaDepartment of Ophthalmology and Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Laura WardEmory University Rollins School of Public Health, Atlanta, Georgia, United States of America.
Carolyn Drews-BotschCollege of Public Health, George Mason University Fairfax, Virginia, United States of America.
Catherine PrattBiosurv International, Salisbury, England, United Kingdom.
Sanjana KuthyarEmory University School of Medicine, Atlanta, Georgia, United States of America.
Alcides Filho FernandesEmory University School of Medicine, Atlanta, Georgia, United States of America.
Ye HuangDepartment of Ophthalmology, University of Illinois Chicago, Chicago, Illinois, United States of America.
Charlene ChooDepartment of Ophthalmology and Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Nam NguyenDepartment of Ophthalmology and Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Jessica CaragDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Jill MorganDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Colleen S KraftDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Angela HewlettDivision of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
David Brett-MajorDivision of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
John S SchieffelinTulane University School of Medicine, New Orleans, Louisiana, United States of America.
Robert F GarryTulane University School of Medicine, New Orleans, Louisiana, United States of America.ORCID 0000-0002-5683-3250
Donald GrantKenema Government Hospital Lassa Hemorrhagic Fever Lab, Kenema, Sierra Leone.
Grant A JustinWalter Reed National Army Medical Center, Washington, D.C. United States of America.
Christopher D ConradyDepartment of Ophthalmology and Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Justine R SmithCollege of Medicine and Public Health, Flinders University, Adelaide, Australia.
Brent R HayekDepartment of Ophthalmology and Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Shiama BalendraUniversity College London, London, United Kingdom.
Nisha AcharyaF.I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States of America.
Thuy DoanF.I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States of America.
Anais LegandWorld Health Organization, Geneva, Switzerland.
Pierre FormentyWorld Health Organization, Geneva, Switzerland.
Xiankun ZengUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, United States of America.
Ibrahim ContehMinistry of Health, Freetown, Sierra Leone.
Matthew J VandyMinistry of Health, Freetown, Sierra Leone.
Lloyd Harrison-WilliamsMinistry of Health, Freetown, Sierra Leone.
Jalikatu MustaphaMinistry of Health, Freetown, Sierra Leone.
Zikan KoromaMinistry of Health, Freetown, Sierra Leone.
Michael WileyDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Ian CrozierClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States of America.
Jean-Claude MwanzaUniversity of North Carolina-Chapel Hill, Chapel Hill, NC, United States of America.
Jessica G ShanthaF.I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States of America.
Rafi AhmedEmory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.
Steven YehDepartment of Ophthalmology and Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
SMILE and EVICT-VR Investigator Study Groups

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Pathogenesis of Uveitis in Ebola Virus Disease SurvivorsR01EY029594 · NEI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI YEH, STEVEN · 2019 to 2023
$2.9M
Ophthalmic Disease and Laboratory Surveillance in a Viral Hemorrhagic Fever ZoneK23EY030158 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHANTHA, JESSICA · 2019 to 2023
$1.2M
NCI NIH HHS 75N91019D00024NEI NIH HHS K23 EY030158NEI NIH HHS R01 EY029594
6 · The paper itself

Abstract

The 2013-2016 Western African outbreak of the Ebola virus disease (EVD), the largest recorded outbreak since the discovery of Ebola virus (EBOV) in 1976, destabilized local health systems and left thousands of survivors at risk for post-acute sequelae, including vision-threatening uveitis. In an EVD survivor with severe panuveitis, the detection of persistent EBOV in the aqueous humor, long after clearance of acute viremia, focused clinical and research attention on the host-EBOV interaction in the unique terrain of ocular immune-privilege. Despite the recognition that uveitis is common and consequential in EVD survivors, our understanding of pathogenesis is extremely limited, including the contributions of viral persistence and ocular-specific and systemic immune responses to disease expression. In this study protocol, we outline a multifaceted approach to characterize EVD-associated intraocular inflammation (EVD-IOI), including the clinical phenotype and complications; the presence of EBOV (or EBOV RNA/antigen) in ocular fluids and tissues; and associated local ocular-specific and peripheral immune responses. We utilize an observational cohort design, which includes EVD survivors and close contacts of EVD survivors (i.e., no documented history of EVD), and we propose disease (clinical examination and imaging), as well as molecular, virologic and immunologic characterization, to meet research objectives. Comprehensive findings emerging from the research will inform local stakeholders and global partners to understand and effectively address the individual and public health implications of EVD-associated uveitis, including to optimize clinical decision-making and medical intervention, identify potential ocular and peripheral biomarkers of viral persistence and ocular disease, and ensure effective infection prevention and control.

Identifiers

PMID40475131
PMCPMC12140520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.